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Abstract: Objective: The coronavirus disease 2019 (COVID-19) pandemic has resulted in
shortages of personal protective equipment (PPE) underscoring the urgent need for
simple, efficient, and inexpensive methods to decontaminate SARS-CoV-2-exposed
masks and respirators. We hypothesized that methylene blue (MB) photochemical
treatment, which has various clinical applications, could decontaminate PPE
contaminated with coronavirus.
Design: The two arms of the study included: 1) PPE inoculation with coronaviruses
followed by MB with light (MBL) decontamination treatment, and 2) PPE treatment with
MBL for 5 cycles of decontamination (5CD) to determine maintenance of PPE
performance.
Methods: MBL treatment was used to inactivate coronaviruses on three N95 filtering
facepiece respirator and two medical mask models. We inoculated FFR and MM
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
materials with three coronaviruses, including SARS-CoV-2, and treated with 10 µM MB
and exposed to 50,000 lux of white light or 12,500 lux of red light for 30 minutes. In
parallel, integrity was assessed after 5CD using multiple US and international test
methods and compared to the FDA-authorized vaporized hydrogen peroxide plus
ozone (VHP+O3) decontamination method.
Results: Overall, MBL robustly and consistently inactivated all three coronaviruses with
99.8 - to >99.9% virus inactivation across all FFRs and MMs tested. FFR and MM
integrity was maintained after 5 cycles of MBL treatment, whereas one FFR model
failed after 5 cycles of VHP+O3.
Conclusions: MBL treatment decontaminated respirators and masks by inactivating
three tested coronaviruses without compromising integrity through 5CD. MBL
decontamination is effective, low-cost and does not require specialized equipment,
making it applicable in all-resource settings.
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Dear Editors of Infection Control and Hospital Epidemiology, 
  
We cannot continue to be oppressed by the COVID19 pandemic.  
  
Whether it be from global underestimation of the far-reaching impact of a pandemic or whether 
due to political ambivalence, our healthcare workers and global citizens do not have the adequate 
supply of personal protective equipment needed to mitigate the spread of SARS-CoV-2. This 
supply shortage requires a decontamination solution that is simple, safe, inexpensive, resource-
light and globally accessible. In our study, the first of its kind, we have shown that methylene 
blue (MB, a common dye) when activated with bright white light, can inactivate human SARS-
CoV-2 on commonly used N95 respirators, medical masks, and community masks without 
degrading the PPE materials.  
  
We represent a consortium of virology labs and mask and respirator integrity testing sites around 
the globe (including the National Institute of Occupational Safety and Health) testing the 
hypotheses that methylene blue with light can inactivate coronaviruses on PPE. Our team is 
comprised of members of the WHO Infection Prevention and Control (IPC) Group, the WHO 
COVID 19 Task Force, and the Centers for Disease Control and Prevention in the US. Three 
different coronaviruses were tested – Human SARS-Co-V-2, Murine Hepatitis Virus (MHV), 
and a porcine coronavirus to understand the inactivation potential of methylene blue.   
  
We leveraged existing clinical evidence of the safety and efficacy of methylene blue and its 
ability to generate singlet oxygen to develop a potential recipe for PPE decontamination. 
Furthermore, we are adding to the literature about the stable integrity of PPE when subjected to 
repeated (X5) cycles of MB decontamination. These data provide guidance and reassurance to 
the PPE wearer that reuse of PPE is not providing additional risk in high exposure environments 
and situations. 
  
In the course of this study, one of our senior researchers lost her husband to COVID19 making 
the need to get our results and message to the globe that more pressing. 
  
All authors have approved this manuscript, contributed significantly to this work, and this 
manuscript has not been previously published in a peer reviewed journal, nor is being considered 
by another journal for publication. We have pre-published the methylene blue details in 
MedRxiv doi: https://doi.org/10.1101/2020.12.11.20236919 
 
 
We suggest the following four thought leaders as potential reviewers for this manuscript: 
 
1) Scott C. Weaver, MS, PhD, Galveston National Laboratory, sweaver@utmb.edu 
2) Trish M Perl, MD, MSc, UT-Southwestern, trish.perl@UTSouthwestern.edu 
3) Daniel G. Bausch, MD, MPH, TM, Public Health England/London School of Hygiene 
and Tropical Medicine, Daniel.Bausch@phe.gov.uk 
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 8 
ABSTRACT  160 
Objective: The coronavirus disease 2019 (COVID-19) pandemic has resulted in shortages of 161 
personal protective equipment (PPE) underscoring the urgent need for simple, efficient, and 162 
inexpensive methods to decontaminate SARS-CoV-2-exposed masks and respirators. We 163 
hypothesized that methylene blue (MB) photochemical treatment, which has various clinical 164 
applications, could decontaminate PPE contaminated with coronavirus.  165 
Design: The two arms of the study included: 1) PPE inoculation with coronaviruses followed by 166 
MB with light (MBL) decontamination treatment, and 2) PPE treatment with MBL for 5 cycles 167 
of decontamination (5CD) to determine maintenance of PPE performance. 168 
Methods: MBL treatment was used to inactivate coronaviruses on three N95 filtering facepiece 169 
respirator and two medical mask models. We inoculated FFR and MM materials with three 170 
coronaviruses, including SARS-CoV-2, and treated with 10 µM MB and exposed to 50,000 lux 171 
of white light or 12,500 lux of red light for 30 minutes. In parallel, integrity was assessed after 172 
5CD using multiple US and international test methods and compared to the FDA-authorized 173 
vaporized hydrogen peroxide plus ozone (VHP+O3) decontamination method. 174 
Results: Overall, MBL robustly and consistently inactivated all three coronaviruses with 99.8 - 175 
to >99.9% virus inactivation across all FFRs and MMs tested. FFR and MM integrity was 176 
maintained after 5 cycles of MBL treatment, whereas one FFR model failed after 5 cycles of 177 
VHP+O3.  178 
Conclusions: MBL treatment decontaminated respirators and masks by inactivating three tested 179 
coronaviruses without compromising integrity through 5CD. MBL decontamination is effective, 180 
low-cost and does not require specialized equipment, making it applicable in all-resource 181 







































































The coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has 185 
resulted in critical personal protective equipment (PPE) shortages, especially filtering facepiece 186 
respirators (FFRs, also known as N95 respirators). Although designed for single use, healthcare 187 
personnel (HCP) are reusing potentially contaminated FFRs and medical masks (MMs) on an 188 
emergency basis due to supply shortages. These shortages have necessitated the rapid 189 
development and deployment of disinfection processes, leading to the World Health 190 
Organization (WHO) issuing interim guidance on rational PPE use (1,2). The US Food and Drug 191 
Administration (FDA) granted Emergency Use Authorization of hydrogen peroxide and steam 192 
sterilization systems to decontaminate FFRs for reuse (3). These technologies remain less 193 
available in low-resource settings, where frontline HCP have inadequate protection (4,5), thus 194 
we need novel methods for PPE decontamination. 195 
 Photochemical disinfection uses a photosensitive chemical, which combined with visible 196 
light generates singlet oxygen (Supplemental Section). Singlet oxygen inactivates viruses by 197 
damaging viral nucleic acids and membranes (6). One such photosensitizer is methylene blue 198 
(MB), which is FDA-approved to treat methemoglobinemia, and used to sterilize human plasma 199 
transfusions in Europe (7). MB inactivates SARS-CoV-2 and many other viruses (8-10) 200 
[Supplemental TABLE S3].  201 
 This Development and Methods for N95 Respirators and Mask Decontamination 202 
(DeMaND) study aimed to evaluate methods that inactivate SARS-CoV-2 on respirators and 203 
masks, which can be applied anywhere at low-cost. We examined if MB with light (MBL) could 204 
effectively decontaminate commonly-used FFRs and MMs while maintaining mask integrity 205 
(filtration, breathability, fluid resistance and fit) after multiple decontamination cycles. We 206 


































































   
 
 10 
virucidal effect on two SARS-CoV-2 isolates (Betacoronavirus) and two coronaviruses requiring 208 
a lower level of biocontainment (the Betacoronavirus murine hepatitis virus (MHV) and 209 
the Alphacoronavirus porcine respiratory coronavirus (PRCV)), and (b) the impact of five cycles 210 
of decontamination (5CD) on PPE integrity [FIGURE 1].  211 
 We selected the number of decontamination cycles based on the Centers for Disease 212 
Control and Prevention (CDC)’s recommended maximum number of donnings as part of crisis 213 
capacity strategies (11). We chose FFRs and MMs based on availability during recent outbreak 214 
responses and variations in shape, material and structure. For integrity testing, we compared 215 
MBL to the FDA-authorized vaporized hydrogen peroxide plus ozone system (VHP+O3) (2). 216 
 217 
METHODS   218 
Respirators and Masks 219 
We tested three FFRs and MM models, both fluid resistant and non-fluid resistant, 220 
[Supplemental Figure S9]. These FFRs are surgical FFRs: National Institute of Occupational 221 
Safety and Health (NIOSH)-approved particulate respirators FDA-cleared as medical devices. 222 
Supplemental TABLE S1 testing matrix. 223 
Viruses 224 
We obtained SARS-CoV-2 isolates from a patient at the George Washington University Hospital 225 
(Lab 1) and from Dr. Darryl Falzarano (VIDO) (GISAID accession ID: EPI_ISL_425177) (Lab 226 
2). We used a SARS-CoV-2 clinical sputum specimen with University of Calgary Conjoint 227 
Health Research Ethics Board approval (ID#REB20-0444). Recombinant MHV strain rA59-E-228 
FL-M and PRCV strain 91V44 have been described previously (12-15).  229 


































































   
 
 11 
We cut FFRs and MMs into 7x10 mm coupons and inoculated them with the maximum available 231 
virus dose of SARS-CoV-2 or MHV on the outer layer (or inner layer where specified) with a 232 
pipette and dried for 20 mins before treatment. Virus was eluted in media by vortex or orbital 233 
rocker. Alternatively, we injected PRCV under the outer layer, and then we excised 34x34 mm 234 
coupons and vortexed in a media-containing tube. We quantified the remaining infectious virus 235 
by median tissue culture infectious dose (TCID50) or plaque assays.          236 
Methylene Blue Treatment   237 
We added 10µM MB to the inoculated coupons or sprayed on intact inoculated masks, dried for 238 
30 minutes protected from light, and exposed to 50,000 lux of white light or 12,500 lux of red 239 
light for 30 min. We used red light at a lower intensity because red light contains a higher 240 
percentage of wavelengths that activate MB. Dark controls were left in the biosafety cabinet with 241 
the light off or covered by aluminum foil (<100 lux).    242 
 For pre-treatment testing, we soaked R3 coupons with MB for >1 hour and dried 2 days 243 
protected from light. We then spotted SARS-CoV-2 on outer or inner mask layers and dried for 244 
20 minutes before exposure to 50,000 lux of white light for 30 min. Intact RM and FW were 245 
sprayed with 7-8mL MB and dried overnight. We added MHV to three points on the outer 246 
surface, dried for 20 minutes, exposed to light (50,000 lux) for 30 min, excised the inoculated 247 
area, eluted, and quantified by TCID50 assay. 248 
Light Sources  249 
The Seattle Children’s Research Institute, George Washington University, University of Calgary, 250 
and Nelson Laboratories used lightboxes developed at Colorado State University and included 251 
4000K Husky LED lights. The University of Alberta used 3500K Husky LEDs. The University 252 
of Liège and Centexbel used a custom lightbox containing horticultural lamps. All laboratories 253 






































































Integrity Testing 256 
We assessed respirator and mask integrity by determining filtration efficiency, breathability, 257 
fluid resistance and fit. We tested FFRs/MMs untreated and after 5CD with VHP+O3 or 10µM 258 
MB plus white light (50,000 lux) or red light (12,500 lux) for 60 minutes. For the VHP+O3 259 
treatment, we used the pre-set cycle (Cycle 1) of Stryker’s STERIZONE VP4 Sterilizer at 41°C.  260 
Filtration Efficiency Testing   261 
We assessed filtration efficiency using NaCl sub-micron charged-neutralized particles ranging in 262 
size from 0.022–0.259µm with a median count diameter of 0.075 ± 0.020µm and a geometric 263 
standard deviation of less than 1.86 to give a mass median aerodynamic diameter of 0.3μm, with 264 
air flow at 85 L/min (simulating inhalation at heavy workload) (16).  We measured bacterial 265 
filtration efficiency (BFE) of MMs using aerosolized droplets containing Staphylococcus 266 
aureus at a 28.3 L/min air flow rate (17,18) [Supplemental Methods and Results]. 267 
Breathability Testing 268 
We assessed breathability by measuring inhalation and exhalation breathing resistances using 269 
standard test methods, and pressure drop measurements for MMs. Additionally, we determined 270 
Sheffield Dummy airflow differences for both FFRs and MMs [Supplemental Methods and 271 
Results]. 272 
Fluid Resistance Testing 273 
Testing of resistance to splash and spray by synthetic blood is required for surgical masks in the 274 
US and fluid-resistant MMs in Europe. We tested fluid resistance for MMs [Supplemental 275 
Methods and Results]. 276 
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We conducted human fit testing with the PortaCount® Pro+ 8038 (TSI). Fit testing was 278 
exempted from ethics board review by both the Research Compliance Office, Stanford 279 
University and the Conjoint Health Research Ethics Board, University of Calgary. We tested 280 
multiple dynamic tasks: regular breathing, heavy breathing, turning head side-to-side, moving 281 
head up-and-down, talking, and bending over breathing. We performed each set of tests twice 282 
and calculated Fit Factor (FF) for each mask. We conducted Manikin fit testing using an 283 
advanced, realistic manikin head and according to the NIOSH/National Personal Protective 284 
Technology Laboratory (NPPTL) Decontaminated Respirator Assessment Plan (16). We 285 
examined the changes in the elastic recovery of the FFR straps and MM ear loops to determine 286 
changes in strap/ear loop integrity after 5CD [Supplemental Methods and Results]. 287 
Statistical Analysis 288 
We calculated means and standard deviations or percent pass of each integrity test method 289 
separately by FFR or MM model. We combined data for integrity test methods conducted at 290 
more than one test site to create overall means and standard deviations or percent pass. We tested 291 
normality of the data distribution using the Shapiro-Wilk test. We calculated significant 292 
differences between untreated and treated FFRs and MMs with Student’s t-tests, Mann-Whitney 293 
U tests, or Fisher’s exact tests (SAS v9.4) (19).   294 
 295 
RESULTS 296 
Methylene blue and light (MBL) tissue culture plate inactivation 297 
To confirm that MBL can inactivate a coronavirus, varying concentrations of MB were mixed 298 
with PRCV and exposed to red light (12,500 lux). Treatment with 0.1µM MB plus light resulted 299 
in complete inactivation. In the absence of additional light, complete inactivation required a dose 300 
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 To confirm the ability of MBL to specifically reduce SARS-CoV-2 infectivity, varying 302 
concentrations of MB were mixed with SARS-CoV-2 and exposed to 50,000 lux of white light. 303 
MB inhibited SARS-CoV-2 infectivity with a dose-dependent effect, with or without exposure to 304 
light. This virucidal effect was enhanced in the presence of light [FIGURE 2B]. 305 
MBL FFR and MM material inactivation  306 
To examine the MBL dose required to decontaminate FFR and MM material inoculated with 307 
SARS-CoV-2 or MHV, we cut coupons from a representative FFR (R3) or MM (FW) and 308 
inoculated and treated with MBL for the indicated time periods. Both viruses displayed 309 
sensitivity to MBL treatment. Using 10µM MB and light resulted in complete inactivation of 310 
SARS-CoV-2 and MHV on both FFR and MM materials after 5 minutes [FIGURE 3A]. Using 311 
1µM MB, we observed complete inactivation after 30 minutes of light exposure, though we 312 
observed a 2-4 log viral titer reduction after 5 minutes. MB treatment in the absence of additional 313 
light also resulted in substantial reduction of viral titers.  314 
 To ensure that MBL can efficiently decontaminate a variety of masks, we tested three 315 
more masks, including two additional FFRs (RH) and (RM), and one additional MM (FH). We 316 
inoculated coupons or intact masks, treated with 10µM MB and exposed to light for 30 minutes 317 
[FIGURE 3B-E], conditions which demonstrated robust inactivation in the previous experiment. 318 
We observed complete inactivation (up to 4 logs) of SARS-CoV-2 for all respirators and masks 319 
tested. Treatment with MB without exposure to white light resulted in substantial virus reduction 320 
[FIGURE 3D]. We observed complete inactivation (4-5 log reduction) of MHV for FH, R3, RH, 321 
and RM masks. A low level of virus was detectable in one replicate for FW [FIGURE 3B]. For 322 
PRCV, which was injected under the outer mask layer, we observed a >5-log virus reduction 323 
after treatment of FH, FW, R3 and RH masks. In contrast, we observed a 3-log reduction in RM 324 
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and viruses ranged from 99.8->99.9%[TABLE 1]. In addition, we tested the effect of MBL 326 
inactivation on FFR and MM straps inoculated with PRCV and noted 2-4 log reduction in titers 327 
[Supplemental FIGURE S4]. 328 
Evaluation of Potential Applications of MBL in a Clinical Setting  329 
We examined three potential applications of MBL in a clinical environment. First, since some 330 
clinical settings may not have access to bright light, we investigated whether 10µM MB and 331 
ambient light would be sufficient to inactivate SARS-CoV-2. MB treatment and exposure to 700 332 
lux (ambient light generated by light in a biosafety cabinet) for 60 minutes inactivated nearly 5-333 
logs of SARS-CoV-2. MB and <100 lux of light inactivated almost 3-logs of virus [FIGURE 334 
4A].  335 
Second, we investigated the possibility of pre-treating respirators or masks with MB. We 336 
treated coupons with 10µM MB, dried overnight, and inoculated them with SARS-CoV-2 on 337 
either the hydrophobic outer layer or the hydrophilic inner layer before exposure to 50,000 lux of 338 
white light for 30 min. We could not recover infectious virus from either side of the light-339 
exposed coupons, signifying inactivation of >4 logs of virus [FIGURE 4B]. We sprayed intact 340 
RM respirators and FH masks with 10µM MB, dried overnight, inoculated with MHV, and 341 
exposed to 50,000 lux of white light for 30 min. No viable virus was recovered. [FIGURE 4D]. 342 
 Lastly, we added 10µl of a clinical specimen (saliva) with a titer of 1.15 x 105 PFU/ml 343 
obtained from a COVID-19 patient onto respirator coupons, and treated with 10µM MB and 344 
white light (50,000 lux) for 30 min. No viable virus was detected post-treatment, thus indicating 345 
the potential for this inactivation method in clinical settings in which viable virus may be 346 
protected by proteinaceous matrixes [FIGURE 4C].  347 
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We employed standard test methods to examine if MBL decontamination affected integrity and 349 
compared results to the FDA-authorized VHP+O3 decontamination method. The following 350 
sections describe each of the integrity test methods and results [Supplemental TABLES S2A-B 351 
for complete results]. Additional testing for MMs included bacterial filtration efficiency, 352 
differential pressure, Sheffield dummy, fluid resistance, and strap/ear loop integrity testing 353 
[Supplemental FIGURES S5-S8].  354 
Filtration Efficiency   355 
FIGURE 5A depicts the filtration efficiency before (untreated) and after 5CD. We expected high 356 
filtration efficiencies for the FFRs as they are all NIOSH-approved N95 FFRs, which requires 357 
≥95% sub-micron filtration efficiency. All FFR models surpassed the minimum 95% filtration 358 
efficiency requirement before and after 5CD. Untreated FW and FH masks achieved 76% and 359 
86% filtration efficiency, respectively. Overall, MBL and VHP+O3 treatment of FFRs and MMs 360 
did not cause any significant differences in the filtration efficiency of the studied models 361 
(p>0.01). MM models continued to meet requirements of differential pressure after 5CD 362 
[Supplemental FIGURE S5 and TABLE S2A]. 363 
Breathability  364 
The resistance to airflow via inhalation and exhalation (breathability), is an indication of the 365 
difficulty in breathing through the respirators or masks. The FFR models achieved 366 
inhalation/exhalation resistances >60% below respective NIOSH 42 CFR Part 84 and EN 149 367 
requirements after 5CD [FIGURE 5B, C]. These resistance changes would not make it harder to 368 
breathe through the mask. MMs demonstrated similar inhalation resistances, and lower 369 
exhalation resistance values compared to FFRs after 5CDs. Both MM models were below their 370 
respective allowable maximum differential pressure limit after 5CD [Supplemental FIGURE S6 371 
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[Supplemental FIGURE S7 and TABLE S2A-B]. The MBL treatment did not affect the 373 
breathability of FFRs or MMs, in terms of either inhalation and exhalation resistances or 374 
pressure drop, respectively.  375 
Fluid Resistance  376 
We evaluated MMs for their fluid resistance and found them to be resistant when challenged 377 
from the outside (conventional challenge direction) but less so from the inside of the mask 378 
[Supplemental FIGURE S8 and TABLE S2A].   379 
Fit Testing 380 
Fit testing measures how well a respirator or mask seals around the contours of the face. A good 381 
fit ensures exchanged air is filtered through the respirator. Human fit testing demonstrated that 382 
respirators maintained quantitative fit values, or fit factors (FF), above 100 after 5CD. In 383 
contrast, VHP+O3 decontamination decreased RH and RM fit to the point of failure [FIGURE 384 
6A]. Note that two VHP+O3 decontamination cycles is the maximum authorized by FDA for 385 
N95 FFRs (20). We also performed human fit testing for the MMs to demonstrate that these 386 
types of masks are not designed to ensure a tight fit [FIGURE 6A]. On some of the VHP+O3-387 
treated FFRs and MMs, human participants noted a “strong acrid odor” and some observed 388 
partial elasticity loss on treated straps and ear loops, and discoloration of the nosepiece foams 389 
(RM only). In contrast, some participants wearing the MBL-treated FFRs noted a “not 390 
unpleasant slight odor” at one of the fit testing sites. In addition to the discoloration, the nose 391 
bridge was more rigid for the three MBL-treated RMs.  392 
 We determined Manikin FF using an advanced, realistic manikin headform which 393 
resulted in similar overall passing of OSHA criterion of 100 FF for all three FFRs [FIGURE 394 
6B](16,21). Observed differences between human and manikin fit can be attributed to testing 395 
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wearers. Overall, MBL decontamination after 5CD did not negatively impact integrity 397 




We demonstrate that MB activated by white or red light effectively inactivates SARS-CoV-2 on 402 
FFR and MM surfaces, and with a clinical specimen, without affecting integrity or fit. MBL can 403 
be applied as a decontamination method for single-use FFRs and MMs. Residual MB on the 404 
mask surface could potentially provide a novel means of continual inactivation of viral particles 405 
to decontaminate a mask while donned, since even under ambient light conditions, MB 406 
inactivated SARS-CoV-2 on mask surfaces. .  407 
 For decades, MB has been recognized to have disinfection capabilities against a range of 408 
viral and bacterial pathogens (7-9,22), and MB is currently used to sterilize plasma for 409 
transfusion (23)and to sterilize convalescent serum for COVID-19 treatment (10).  410 
 MBL is suitable for high- and low-resource settings since MB is inexpensive, globally 411 
available, and does not require specialized equipment. Light sources can vary from white high-412 
intensity lamps to ambient lighting to generate singlet oxygen [Supplemental TABLE S6]. 413 
Future studies are warranted to investigate whether MBL could be used to inactivate additional 414 
pathogens and decontaminate other forms of PPE such as gowns, gloves, and boots.  415 
 One limitation was that we only tested a minority of FFR and MM models, yet there are 416 
approximately 500 NIOSH-approved FFR models, and many others used globally. MBL worked 417 
well on all FFRs and MMs tested, except the “RM” FFR possibly owing to a distinct design 418 
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method’s effectiveness be evaluated for specific FFR models in collaboration with the 420 
manufacturer, and if needed, a third-party laboratory (25).  421 
 During our integrity testing, we did not simulate extended wear or multiple donnings and 422 
doffings, which could affect FFR fit and performance (26,27). In addition, off-gassing of MB or 423 
VHP+O3 was not evaluated. The biocompatibility of MB wearer inhalation was not tested, 424 
however, MB concentrations used were below those administered clinically (intravenously, 425 
orally or intranasally) (7,28,29). If the entire dose of 10M MB sprayed onto a mask was 426 
inhaled, which is unlikely, the total inhaled dosage would be 0.02 mg. The quantity of MB 427 
inhalation overtime while wearing a MB-pretreated mask is under investigation.  428 
 We generalized our findings by demonstrating complete MBL inactivation employing the 429 
same methodology across multiple virology laboratories using three coronavirus species and a 430 
SARS-CoV-2 clinical sample.  This signifies that emergent variants of SARS-CoV-2 would also 431 
be inactivated by MBL and that viruses requiring lower levels of biocontainment can be used for 432 
similar inactivation studies. Integrity tests in multiple testing centers using heterogeneous light 433 
administration methods reaffirms the reproducibility of our findings and we replicated practical 434 
light scenarios expected in the real-world settings. 435 
In conclusion, MBL treatment inactivates SARS-CoV-2 on FFRs and MMs without 436 
decreasing integrity and fit. Our findings provide a method for inexpensive, accessible, effective 437 
decontamination of PPE for reuse, applicable in high- and low-resource settings during supply 438 
shortages. Pretreatment of masks with MB could provide a novel means of continual disinfection 439 
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Table 1: Virus Reduction by 10 μM Methylene Blue with Light    
  MHV bPRCV 
Lab 1       
SARS-CoV-2 
Lab 2       
SARS-CoV-2 
Avg.         
SARS-CoV-2 Overall avg. 




























































































































    
RH 4.4 >99.9% 5.5 >99.9% 2.2 >99.4% 4.3 >99.9% 3.2 99.6% 4.1 99.8%    
RM 3.5 >99.9% 2.7 99.8% 2.8 >99.8% 4.0 >99.9% 3.4 99.9% 3.2 99.9%    
R3 5.1 >99.9% 5.0 >99.9% a3.3 >99.9% 3.1 >99.9% 3.2 >99.9% 4.1 >99.9%    
FW 5.8 >99.9% 5.5 >99.9% a3.6 >99.9% 3.1 >99.9% 3.4 >99.9% 4.5 >99.9%    
FH 3.8 >99.9% 5.1 >99.9% 3.1 >99.9% 4.2 >99.9% 3.6 >99.9% 4.0 >99.9%    
aData extracted from inactivation curve. 
bLight source for testing MB on PRCV = 12500 lux red light; Light source for testing MB on all other virus types = 
50000 lux white light. 
Due to the limit of detection of the assays used to titer the virus, the highest % inactivation is indicated as >99.9%. 
Abbreviations: RH, Halyard duckbill respirator (Fluidshield-46727); RM, 3M half-sphere respirator (1860); R3, 3M 
Panel respirator (1870+);  
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Figure legends 580 
FIGURE 1. Graphical representation of the DeMaND study methodology. (A) Overview of the 581 
coronaviruses, respirators, masks and decontamination methods used. (B) FFRs and MMs were 582 
inoculated with virus and treated with MB and light (MBL). Remaining infectious virus was 583 
quantified using TCID50 or plaque assay. (C) In parallel with the virucidal testing of MBL, intact 584 
FFRs and MMs were subjected to 5 cycles of decontamination before mask integrity was tested 585 
using the indicated methods. PRCV = porcine respiratory coronavirus, SARS-CoV-2 = severe 586 
acute respiratory syndrome coronavirus 2, MHV = murine hepatitis virus, MBL = methylene 587 
blue + light, VHP+O3 = vaporized hydrogen peroxide plus ozone. See Supplemental Table S1 588 
for the respirator and mask decontamination and testing matrix. 589 
FIGURE 2. Inactivation of PRCV and SARS-CoV-2 using methylene blue and light 590 
(MBL). (A) To determine the efficacy of different MB concentrations, we added serial dilutions 591 
of MB to wells of a 48-well plate containing 10 µL PRCV (2x107 TCID50/ml). Plates were either 592 
exposed to red light (12,500 lux) for 30 minutes or were protected from light (<100 lux). Dotted 593 
line indicates limit of detection. (B) We added serial dilutions of MB to wells of a 12-well plate 594 
containing ~50 PFU of SARS-CoV-2 in MEM plus 15% FCS. Plates were either exposed to white 595 
light (50,000 lux) for 45 min or protected from light (<100 lux). We determined viral titers using 596 
2-3 replicate samples. ND= not detected. 597 
FIGURE 3. MBL inactivates MHV, SARS-CoV-2, and PRCV on FFR and MM material. (A) 598 
Effect of methylene blue and light treatment on MHV and SARS-CoV-2 titers. We applied a 10 µl 599 
aliquot of MHV or SARS-CoV-2 to coupons derived from a FFR (R3) or MM (FW) and they were 600 
left to dry for 20 min. Subsequently, we added 10 or 30 µl of MB to each coupon at the indicated 601 
concentrations. We exposed the samples to white light (50,000 lux) for the indicated time periods 602 
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replicate samples by TCID50 or plaque assay. . (B-D) We applied a 10 µl aliquot of SARS-CoV-2 604 
or MHV to coupons of the indicated masks and dried for 20 min. Depending on coupon size, we 605 
added 10-30 µl of 10 µM MB to each coupon, and treated the samples with light (50,000 lux) or 606 
protected them from light. (E) We injected 100 µl of PRCV under the outer layer of intact MMs 607 
or FFRs and allowed them to dry for 30 minutes. Subsequently, we sprayed the FFRs and MMs 608 
with 10 µM MB and dried them for 30 minutes in the dark before exposure to red light (12,500 609 
lux). We determined each virus titer using 2-6 replicate samples by TCID50 or plaque assay. Data 610 
is represented as mean +/- SD. ND = Not detected. RH= Halyard duckbill respirator 611 
(Fluidshield-46727). RM= 3M half-sphere respirator (1860). R3= 3M panel respirator (1870+). 612 
FW= Type II EN 14683 generic face mask. FH= Type IIR ASTM F2100 Level 2 Halyard face 613 
mask. Dotted line indicates limit of detection. 614 
FIGURE 4. Potential applications of MBL in a clinical setting. (A) Effect of low light levels on 615 
SARS-CoV-2 inactivation using MB. We applied a 10 µl aliquot of SARS-CoV-2 to R3 coupons 616 
and dried for 20 min. We added 10 µL of 10 µM MB to each coupon before treatment with 700 617 
lux or <100 lux of light (the light level produced by the biosafety hood lights). (B) Effect of MB 618 
pre-treatment on SARS-CoV-2 inactivation. We cut coupons from R3 masks and soaked for 1 hr 619 
in 10 µM MB. We then dried the coupons in the dark for 2 days before adding 10 µl of virus to 620 
either the inner or outer layers. We exposed the samples to white light (50,000 lux) for 30 min 621 
and determined the virus titer by plaque assay. (C) Inactivation of a SARS-CoV-2 clinical 622 
specimen by MBL. We obtained a saliva specimen from a COVID-19 patient with a titer of 1.1 x 623 
105 PFU/ml for SARS-CoV-2. We applied 10 µl aliquots to coupons cut from a R3 mask and 624 
treated with 10 µM MB and exposed to white light (50,000 lux) for 30 min. We determined virus 625 
titer by plaque assay. (D) Effect of MB pre-treatment on MHV inactivation using intact masks. 626 
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total of 7-8 ml of MB and allowing to dry overnight in the dark. We inoculated the dried masks 628 
with MHV and exposed to white light (50,000 lux) for 30 minutes. We then excised inoculated 629 
areas before elution and titration. We determined virus titer by TCID50 assay. ND = Not 630 
detected. RM= 3M 1860 half-sphere respirator. FH= Type IIR Halyard face mask. Dotted line 631 
indicates limit of detection. 632 
FIGURE 5. Effect of MBL and VHP+O3 treatments on NaCl sub-micron filtration efficiencies 633 
and breathability before and after 5CD. (A) NaCl sub-micron filtration efficiency is a measure 634 
of the ability of an FFR or MM to capture aerosolized particles smaller than one micron, 635 
expressed as a percentage of particles that do not pass the material at a given velocity or flow 636 
rate. (B) Inhalation and (C) exhalation breathing resistances before and after 5CD. The 637 
resistance to airflow during inhalation and exhalation is an indication of the difficulty in 638 
breathing through the respirators/masks. *Results from decontaminated FFRs and MMs are 639 
significantly different from untreated masks (Student’s t test or Mann-Whitney U test 640 
p<0.01).RH= Halyard duckbill respirator (Fluidshield-46727). RM= 3M half-sphere respirator 641 
(1860). *Horizontal solid line represents the N95 filtration efficiency requirement of ≥95% 642 
particle filtration efficiency according to 42 CFR Part 84. **Horizontal lines represent the 643 
following breathing resistance standards: Inhalation: ≤35 mmH2O; exhalation: ≤25 mmH2O for 644 
respirators according to 42 CFR Part 84. Note: EN 149 maximum inhalation resistance at 95 645 
L/min is 2.4 mbar, or approximately 24 mmH2O. At higher flow rate according to EN 149, the 646 
equivalent breathing resistance may increase slightly but can be similar to the 42 CFR Part 84 647 
maximum inhalation resistance at 85 L/min. 648 
RH= Halyard duckbill respirator (Fluidshield-46727). RM= 3M half-sphere respirator (1860). 649 
R3= 3M panel respirator (1870+). FW= EN 14683 Type II generic face mask. FH= ASTM 650 
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FIGURE 6. Effect of MBL and VHP+O3 treatments on human and manikin fit factor of 652 
FFR/MMs. (A) We performed human fit testing with volunteer participants who adjusted the 653 
FFR and MM to achieve the highest fit factor or seal and subsequently performed head 654 
movements and remeasured fit or seal. (B) Manikin fit factors using advanced, realistic manikin 655 
headforms is a reproducible method to test fit without volunteer participants. We used the 656 
PortaCount® PRO+ 8038 machine to determine overall fit for both human participants and 657 
manikins headforms. *Indicates significantly different values between treated and untreated FFR 658 
or MM at p<0.05, Student’s t- test or Mann-Whitney U test, as appropriate. **Horizontal line 659 
represents the following standard: ≥100; OSHA 29 CFR 1910.134(f)(7). Percentages on or 660 
above each bar represents % of respirators or masks tested that surpassed this standard. While 661 
the standard does not apply to face masks, we present the % to note the strong difference 662 
between respirator and face mask test results. †Horizontal solid line represents the following 663 
standard: Per OSHA 1910.134(f)(7), if the Overall Fit Factor as determined through an OSHA-664 
accepted quantitative fit testing protocol is equal to or greater than 100 for tight-fitting half 665 
facepieces, then the fit test has been passed for that respirator. RH=Halyard duckbill respirator 666 
(Fluidshield-46727). RM=3M half-sphere respirator (1860). R3=3M panel respirator (1870+). 667 
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